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Natural products have played a significant role in the drug discovery especially in 
the area of cancer.  Over the period of 1940-2010, 50% of the small molecules 
introduced as anticancer agents were either natural products or directly derived 
therefrom.   In one of the ongoing collaborative project to identify anticancer leads, 
the Mycosynthetix library, representing over 55,000 accessions of filamentous fungi, 
is being examined systematically.  The bioactive-guided fractionation methodology is 
adopted for the isolation and purification of cytotoxic lead compounds.  The first 
chapter describes the isolation of cytotoxic secondary metabolites using bio-activity 
guided fractionation scheme.  
As part of ongoing investigations of filamentous fungi for anticancer drug leads, a 
bioactivity-guided fractionation methodology utilizes chloroform in the initial 
extraction and fractionation processes.  Due to the concerns regarding human health 
and halogenated waste associated with chloroform, an attempt was made to replace 
it with more environmentally benign ester-based solvents.  In this project, ethyl 
acetate, methyl acetate and ethyl formate were used in the initial stages of 
extractions and processing.  The extraction efficiency of these was compared versus 
chloroform using two well-studied fungi.
       
 
 
BIOACTIVE NATURAL PRODUCTS: ISOLATION OF  
FUNGAL SECONDARY METABOLITES AND  
APPLICATIONS OF GREEN  
CHEMISTRY   
 
 
 
by 
 
Rabia M. Bukhari 
 
 
 
 
A Thesis Submitted to  
the Faculty of the Graduate School at  
The University of North Carolina at Greensboro  
in Partial Fulfillment  
of the Requirements for the Degree  
Master of Science 
 
 
 
 
Greensboro 
2013 
 
 
 
 
     Approved by 
 
                
     Committee Chair  
 
   
ii 
 
APPROVAL PAGE 
 
 
 This thesis written by RABIA BUKHARI has been approved by the following 
committee of the Faculty of The Graduate School at The University of North Carolina at 
Greensboro. 
 
 
Committee Chair 
 
Committee Members 
 
  
 
 
 
 
 
  
Date of Acceptance by Committee
 
Date of Final Oral Examination  
 
 
   
iii 
 
TABLE OF CONTENTS 
 
Page 
 
LIST OF TABLES ............................................................................................................. iv 
 
LIST OF FIGURES .............................................................................................................v 
 
CHAPTER  
 
 I. MINIMIZING THE ENVIRONMENTAL FOOTPRINT OF  
  NATURAL PRODUCTS .................................................................................1 
 
 Introduction ..................................................................................................1 
 Alternative Solvent Selection Strategy ........................................................7 
 Solvent Selection. ........................................................................................9 
 Method .......................................................................................................11 
 Results ........................................................................................................13 
 Conclusion .................................................................................................20 
 
 II. ISOLATION AND STRUCTURE ELUCIDATION OF  
   CYTOTOXIC SECONDARY METABOLITES FROM  
    FILAMENTOUS FUNGI ................................................................................21 
 
 Method .......................................................................................................23 
 Results And Conclusion .............................................................................30 
 
REFERENCES ..................................................................................................................42 
   
iv 
 
LIST OF TABLES 
 
Page 
 
Table 1. Esters and their properties compared to solvents 
 presently used for extraction ............................................................................10 
 
Table 2. Cost comparisons of alternative solvents to CHCl3 ............................................14 
 
Table 3. Average of extract yields (mg) of MSX63935 for multiple 
 rounds of extraction in solvents ......................................................................16 
 
Table 4. Bioassay data obtained for flash chromatography fractions of 
 MSX47782* .....................................................................................................27 
 
Table 5. Preparative HPLC fractions (01020-37-2) pooled based on the 
  chromatogram ..................................................................................................30 
 
Table 6. NMR Data for Compound 1 (700 MHZ for 1H, 176 MHz for 13C;  
 Chemical Shifts in δ, CDCL3) ........................................................................39 
 
Table 7.  Comparison of 1H and 13C NMR data of Compound 2 (δ in ppm) 
 with literature Cytochalasin H., recorded in CDCl3 at 17°C at  
 500 MHz for 1H and 125 MHz for 13C .........................................................41 
 
 
 
 
 
 
 
 
 
 
 
   
v 
 
LIST OF FIGURES 
 
Page 
 
Figure 1. Extraction and partition scheme for filamentous fungi on rice ............................4 
 
Figure 2. Criteria for choosing an alternative green solvent ................................................6 
 
Figure 3. Structures of resorcylic acid lactones (zeaenols) in MSX63935  
 and secalonic acids in MSX45109 ..................................................................15 
 
Figure 4. UPLC chromatogram stack plot of extract of fungus MSX63935 
  in CHCl3 versus EtOAc extract .....................................................................18 
 
Figure 5. UPLC chromatogram stack plot of extract of fungus MSX45109 
  in CHCl3 versus EtOAc extract .....................................................................19 
  
Figure 6. ISCO flash chromatography of organic extract from MSX47782* ...................26 
 
Figure 7. a) Preparative HPLC chromatogram of 01020-37-2 @ 335 nm 
 and b) the chromatogram showing fractions ....................................................29 
 
Figure 8. Structure of New Compound 1 (01021-86-2) ....................................................32 
 
Figure 9. HRMS spectrum for Compound 1 (01021-86- 2) ..............................................33 
 
Figure 10. 13C NMR of Compound 1 (CDCl3) ................................................................34 
 
Figure 11. 1H NMR spectrum of Compound 1 (01021-86-2)  ..........................................35 
 
Figure 12. COSY Spectrum of Compound 1 (01021-86-2) ...............................................36 
 
Figure 13. HMBC spectrum of Compound 1 (01021-86-2) ..............................................37 
 
Figure 14. HSQC-edited NMR spectrum of Compound 1 (01021-86-2) ..........................38 
 
Figure 15. Chemical structures of compounds 2-3 ............................................................40 
   
1 
CHAPTER I 
 
MINIMIZING THE ENVIRONMENTAL FOOTPRINT OF NATURAL PRODUCTS* 
 
 
     *This chapter will be submitted to the Journal of Green Chemistry. 
 
 
Introduction 
Since the introduction of the term “green chemistry” 20 years ago by Drs. Paul T. 
Anastas and John C. Warner, extensive research has been conducted in all fields of 
chemistry worldwide.  One of the 12 principles proposed by Anastas and Warner was “to 
use safer solvents and auxiliaries”,1 thereby raising awareness of toxic reagents and/or 
organic solvents in chemistry research and their impact on humans and the 
environment.  Thus, the use of more green solvents is one means to minimize the 
environmental impact of chemistry research.2   
Recently, Taygerly et al.3 proposed a solvent selection guide for choosing solvent 
alternatives to dichloromethane (CH2Cl2) in chromatography procedures used frequently 
in medicinal chemistry.  While the scale of medicinal chemistry may be smaller than that 
of process chemistry, a large amount of waste can be generated across disparate labs. 
Inspired by their work, we embarked on a similar journey to identify solvent alternatives 
greener than chloroform for the extraction of natural products.  However, there is a 
fundamental difference between medicinal and natural products chemistry research.
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In the former the structures of starting materials and products are known in advance.  
In fact, Taygerly et al.3 use this to their advantage when predicting what solvents could 
be used to replace CH2Cl2 in chromatographic purifications.  In contrast, in the early 
stages of natural products research, the structures are not known.  Hence, if CHCl3 were 
to be replaced in initial processing steps, a solvent that was “general” enough to dissolve 
a broad and often unknown series of structures was desired.  While there have been 
countless advances in the separation techniques utilized for isolating natural products, 
there has been less emphasis placed on strategies to minimize or find alternatives to 
solvents used most frequently.   
Previous Jessop4 presented four grand challenges scientists face when introducing 
green solvents in to procedures: 1) finding an appropriate green solvent; 2) being able to 
identify whether a solvent is in fact green; 3) finding polar aprotic solvents that are easily 
removed; and 4) finding ways to eliminate distillation.  These challenges, particularly 1 
through 3, were considered while striving to minimize the halogenated waste associated 
with natural product extraction procedures. 
In ongoing studies to explore nature for anticancer drug leads,5,6 extracts of 
filamentous fungi from the Mycosynthetix library, representing over 55,000 accessions, 
are being investigated systematically for bioactive secondary metabolites.  In the initial 
stages of extraction and fractionation, a suite of solvents are used, particularly 
chloroform (Figure 1).  Its volatility makes it easy to evaporate.  Its polarity, being 
between the extremes of hexane and H2O, impart it with an ability to dissolve a diverse 
array of compounds.7  Moreover, its specific gravity is greater than that of H2O, making it 
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convenient for use in simple apparatus, like separatory funnels.  Hence, chloroform is 
used frequently for extracting, bioactive secondary metabolites from fungal cultures.   
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Figure 1. Extraction and partition scheme for filamentous fungi on rice. a) CHCl3 
used as an extraction solvent in the initial two stages and b) EtOAc used in place 
of CHCl3 in the initial two stages. 
 
 
 
 
a) 
b) 
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Despite those conveniences, several research studies that applied environmental, 
health and safety assessment and life-cycle assessment ranked chloroform 
unfavorable.8  The costs associated with halogenated waste are high and improper 
handling may have carcinogenic effect.9  For example, the US Environmental Protection 
Agency (EPA), following the Pollution Prevention Act of 1990, compiled a list of 17 
priority pollutants known as EPA 33/50. Chloroform is the third solvent on the list, 
predominantly due to its anticipated human carcinogenicity.10   
The UNCG Department of Environmental Health and Safety reported close to 20,000 
pounds of waste generated at UNCG in last fiscal year out of which 1730 containers 
were marked as hazardous waste.   UNCG spends close to $20,000 per year on waste 
management, and the Department of Chemistry and Biochemistry’s’ hazardous waste 
disposal costs somewhere from $1000 up to $5000 per year.  In the light of these 
statistics, and the UNCG waste minimization policy, it would be beneficial to reduce the 
amount of hazardous waste generated on campus.   
The goal of the present study was to replace chloroform with an alternative solvent 
that was low in toxicity, environmentally benign, and inexpensive, all without introducing 
significant changes to the well-established procedures or, most importantly, 
compromising extraction efficiency (Figure  2).  Various ‘green solvent’ options listed in 
the literature were investigated, and their extraction efficiencies versus chloroform, were 
evaluated using two well-studied fungal cultures, MSX63935 and MSX45109.  To do so, 
the yields and chromatographic profiles of key compounds were compared using Ultra 
Performance Liquid Chromatography (UPLC).  
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Figure 2. Criteria for choosing an alternative green solvent. 
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Alternative Solvent Selection Strategy 
Substantial research effort is directed towards searching for alternative green 
solvents.  As reported by Jessop4, approximately 41% of the papers published in Green 
Chemistry in 2010 were on ionic liquids, 28% on water, 11% on processes using no 
solvent, and a relatively small number on the use of carbon dioxide.  In this research 
project, these particular replacements were considered as possible green alternatives to 
chloroform. 
Ideally, the best option available in terms of reducing waste would be the use of no 
solvent.  Contrary to this, most of the ‘solvent free’ procedures reported in the literature 
used solvents at some stage.  The amount of solvent used in these procedures were 
reduced compared to the conventional approaches, and therefore the methods were 
considered green.11  For the extraction of secondary metabolites from filamentous fungi, 
a solvent of some kind was required. 
Water maybe the second best candidate for a green solvent as it is plentiful and 
inexpensive.  However, most secondary metabolites have limited solubility in H2O, 
eliminate this option. 
Ionic Liquids are considered designer solvents specific for a process or reaction.   
Which are salts with low melting points, and they are popular as an alternative to volatile 
organic solvents (VOC), due to low vapor pressures.  However, due to the limited data 
available on toxicity and environmental impact, they cannot be considered green.2  Also, 
their cost is prohibitive.12  
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Carbon dioxide exists as supercritical CO2 (scCO2) above a critical pressure and 
temperature.  Due to its volatile nature, scCO2 is a well-established extraction solvent for 
natural products. By simply releasing the pressure, “solvent” is completely removed.12  It 
has very little environmental impact.  However, the biggest disadvantage of scCO2 is the 
high equipment cost, limiting its usage in research community.  
Another interesting class of solvents is esters.  Esters are generally considered 
environmentally friendly solvents, and they have relatively low health hazards. For 
example, ethyl lactate has become widely available as a bio-sourced and biodegradable 
cleaning fluid11.  Ethyl lactate is prepared by esterification of lactic acid and ethanol; both 
of them are renewable sources and maybe obtained from fermenting corn starches.  It is 
readily purified as it is prepared from natural resources and it is completely 
biodegradable to carbon dioxide and water.  Methyl acetate (MeOAc) is useful as a fast-
evaporating solvent in applications like coating and ink resins where fast solvent 
releases are needed.  Ethyl acetate (EtOAc) is normally produced by esterification of 
ethanol and acetic acid.  Currently, it is used in industrial lacquers and surface coating 
resins.13  Furthermore, it is also used as an extraction solvent in the production of 
pharmaceuticals and food, especially in decaffeination of green tea.7 
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Solvent Selection 
For a solvent to be considered as an alternative to chloroform in our lab set up, it 
should meet certain conditions.   With this in mind, the following green solvent selection 
criterion was developed; (1) it needs to be volatile – easily evaporated; (2) extraction 
efficiency (product yield) has to be equal or higher than chloroform; (3) it must be low in 
cost and easily available for purchase; (4) extraction and partition procedure shouldn’t 
be changed significantly (Figure 2).   
With these criteria in mind, esters proved to be a better alternative solvent.  But, 
which ester solvent is an optimal solvent for extraction of secondary metabolites from 
filamentous fungi?  Ideally, the aim was to find an ester that had similar properties to 
chloroform; immiscible or has low solubility in water to give high product yield and having 
a boiling point lower than n-butanol (preferably lower than 80°C).  In general, solvents 
with high boiling points are avoided due to longer evaporation time and high energy cost 
associated with separation by distillation.14   
To assist with the solvent selection, in total six esters were evaluated.  Esters were 
systematically listed according to their increasing carbon-chain lengths and properties 
like boiling point, cost per liter (US $), polarity index, density and solubility in water were 
compared to that of chloroform (Table 1). 
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Table 1. Esters and their properties compared to solvents presently used for 
extraction. 
 
Solvent Structure 
BP     
(°C) 
Cost      
(per L in 
US $) 
Polarity 
Index 
Density 
(g/cm3) 
Solubility 
in H2O 
(g/L) 
 
Ethyl acetate 
 
 70 4 4.3 0.90 80
Ethyl lactate 
 
 
154 29 7.6 1.03 Miscible
Methyl acetate 
 
 56 33 4.4 0.93 250
Ethyl formate 
 
 54 37 4.3 0.92 110
n-Propyl acetate 
 
 102 5 4.2 0.89 20
n-Butyl acetate 
 
 126 27 4.0 0.88 7
Chloroform CHCl3 61 11 4.1 1.48 8
n-Butanol  118 15 4.0 0.81 80
Methanol CH3OH 65 0.95 5.1 0.79 Miscible
 
 
O
OH
O
H O
O
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Ethyl lactate, n-propyl acetate and n-butyl acetate were eliminated due to their higher 
boiling points in comparison with n-butanol.  Additionally, ethyl lactates’ miscibility in 
water made it an unfavorable extraction solvent.  Although MeOAc had a higher 
solubility in water than preferred, the low boiling point made it an eligible candidate for 
analysis.   
EtOAc, MeOAc and ethyl formate were further investigated in an attempt to replace 
CHCl3 as an extraction solvent for filamentous fungi.  In order to assess the extraction 
efficiency of these solvents versus CHCl3, they were tested against well-studied 
filamentous fungi, MSX63935 and MSX45109.   
Method 
General experimental information: 
The fresh cultures of MSX63935 and MSX45109 on rice medium, from 
Mycosynthetix library were grown in parallel.  To check solvents’ extraction 
reproducibility, three separate rounds of extractions were done for each solvent.  All 
solvents used for analysis were obtained from Fischer Scientific and were used without 
further purification.  The solvent prices were obtained from PHARMO-AAPER at UNCG 
contracted price.  UPLC was carried out on Waters Acquity system with data collected 
and analyzed using Empower software. 
Producing Organisms And Fermentation: 
Mycosynthetix fungal strain MSX63935 was isolated in 1992 from a leaf litter and the 
fungal strain MSX45109 was isolated in 1989 from a stump of banana tree in a 
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mangrove area, by Dr. Barry Katz of MYCOsearch. The cultures were stored on a malt 
extract slants and were transferred periodically.  Fresh cultures were grown on a similar 
slant, and a piece was transferred to a medium containing 2% soy peptone, 2% 
dextrose, and 1% yeast extract (YESD media).  Following incubation (7 days) at 22°C 
with agitation, the cultures were used to inoculate 50 mL of a rice medium, prepared 
using rice to which was added a vitamin solution and twice the volume of rice with H2O, 
in a 250 mL Erlenmeyer flask.  This was incubated at 22°C until the cultures showed 
good growth (approximately 14 days) to generate the screening cultures.14, 15 
Extraction And Fractionation: 
To each flask of solid fermentation culture, a mixture of 60 mL of 1:1 
methanol/solvent was added (solvent = either CHCl3, EtOAc, MeOAc, or Ethyl formate).  
Then, the samples were chopped with a spatula and stirred overnight (16 h) in a shaker 
at 100 rpm at room temperature.  The samples were filtered by vacuum filtration into 250 
mL sidearm flasks.  The remaining residues were washed with small volumes of MeOH.  
To the filtrate, 90 mL of the investigated solvent and 150 mL of H2O were added.  The 
biphasic solutions were stirred on a stir plate for 30 min, and then transferred to 
separatory funnels. 
The bottom layers for CHCl3 were drawn off into round-bottom flasks and evaporated 
to dryness.  For EtOAc, MeOAc and ethyl formate, top layers were drawn off into round-
bottom flasks and evaporated to dryness.  The organic extracts were then brought up in 
50 mL of 1:1 ACN/MeOH and 50 mL of hexanes.  The biphasic solutions were mixed for 
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an hour and transferred to separatory funnels.  The ACN:MeOH layer were evaporated 
to dryness under vacuum and yields were taken. 
UPLC Analysis: 
Chromatography was performed using an Acquity UPLC BEH C18 (2.1 × 50 mm, 1.7 
µm) column (Waters Corp., Milford, MA, USA) equilibrated at 30 °C. A mobile phase 
consisting of ACN and H2O (acidified with 0.1% formic acid) was used, starting with 
40:60 ACN/H2O, going to 55:45 over 5 min, then re-equilibrating at 40:60 for 1 min. 
Chromatograms were collected at 233 nm. 
Results 
EtOAc, MeOAc and ethyl formate were used as solvents to extract secondary 
metabolites from well-studied fungi, designated by MSX63935 and MSX45109.  CHCl3 
was used as a control to compare the extraction efficiencies.  Analyses were carried out 
in five replicates to test the reproducibility of the solvents.  
In our research lab, investigation of filamentous fungi for anti-cancer leads is the 
largest project.  The group continually searches fungal extracts from the Mycosynthetix 
library throughout the year.  On average, some 400 small-scale solid culture samples 
are being processed every year.  In the light of that, it is imperative for us to compare the 
costs of EtOAc, MeOAc, ethyl formate against CHCl3 (Table 2). 
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Table 2. Cost comparison of alternative solvents to CHCl3. 
 
 
1 fungus sample 
extraction (L) 
400 samples per 
year (L) 
Cost per liter 
(US $)  
Total cost            
(US $ per year) 
Chloroform 0.15 60 11 660 
Ethyl acetate 0.15 60 4 240 
Methyl acetate 0.30 120 33 3960 
Ethyl formate 0.15 60 37 2220 
 
Method Validation: 
MSX63935: Previous research on an extract of filamentous fungi, MSX63935, 
showed promising cytotoxic activity against a human tumor panel. These results 
commenced a bioactivity-directed fractionation study and a series of resorcylic acid 
lactones (zeanols) were isolated and characterized (Figure 3).14 
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Figure 3. Structures of resorcylic acid lactone (zeaenols) in MSX63935 and 
secalonic acid in MSX45109. 
 
MSX63935 
 
O
OOH
H3CO
OH
OH
OH  
O
OOH
H3CO
O
OH
OH  
Zeaenol (1) 7-epi-zeaenol (2) 5E-7-oxozeaenol (3) 
   
 
5Z-7-oxozeaenol (4) LL-Z1640-1 (5)  
MSX45109  
 
Secalonic acid A (6) Secalonic acid G (7) Secalonic acid E (8) 
 
 
MeOAc fractions had relatively high yields (375 mg) compared to the other solvents 
(Table 3).  The two solvents, MeOAc and H2O, were miscible in each other at the ratio 
that was used in the standard procedure.  Hence, additional MeOAc was added to get 
the phases separated, thus increasing costs, time and higher yields. 
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Table 3. Average of extract yields (mg) of MSX63935 for multiple rounds of 
extraction in solvents. 
 
The extraction yield of EtOAc (348 mg) was analogous to that of CHCl3 (322 mg) 
(Table 3).   Ethyl formate also had a yield (313 mg) comparable to CHCl3 extracts but 
with a much higher solvent cost; it does not make for a cost effective alternative solvent. 
The yields and chromatographic profiles of key compounds in MSX63935 were 
compared with EtOAc, MeOAc and ethyl formate against CHCl3 using UPLC.  The stack 
plot of extract of MSX63935 in CHCl3 and EtOAc were compared (Figure 4).  The 
percent peak area was calculated by averaging the percent peak area for the replicates 
done in particular solvent.  EtOAc and ethyl formate had similar peak areas to CHCl3 for 
most of the compounds.  Due to the high cost associated with ethyl formate it was 
eliminated as not being very economical and MeOAc miscibility in H2O caused excess 
use of the solvent, therefore cannot be considered very green.   
MSX45109:  To check the efficiency of EtOAc as an extraction solvent, another well-
studied fungus MSX45109 was extracted with CHCl3 and EtOAc.  This fungus was found 
to produce dimeric ergochromes, also known as secalonic acids, a biologically important 
class of mycotoxins (Figure 3). 
 Yield mg ± SD(%RSD) 
Chloroform 322 ± 73(23) 
Ethyl acetate 348 ± 88(25) 
Methyl acetate 375 ± 105(28) 
Ethyl formate 313 ± 52(17) 
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There are 3 distinct peaks in the UPLC chromatogram (Figure 5).  The yields and 
chromatographic profiles were compared for CHCl3 and EtOAc.  The average yield of 5 
rounds of extraction in CHCl3 was 149 mg ± 21 and in EtOAc it was 144 mg ± 9.  
Secalonic acid A, secalonic acid G and secalonic acid E were distinct in both 
chromatograms.  The total percent peak area for all the secalonic acids extracted in 
EtOAc were very similar to the CHCl3extract. 
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Figure 4. UPLC chromatogram stack plot of extract of fungus MSX63935 in CHCl3 
versu EtOAc extract. 
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Figure 5. UPLC chromatogram stack plot of extract of fungus MSX45109 in CHCl3 
versus EtOAc extract.   
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Conclusion 
The extraction with EtOAc yielded the best results based on UPLC chromatogram 
and  the peak areas per milligram were very similar between CHCl3 and EtOAc.  
Additionally, EtOAc is confirmed to be a good alternative solvent for CHCl3 as it gave 
similar yields to CHCl3 and it is much less expensive.  EtOAc is also considered a 
greener solvent, as it has a much lower environmental impact and a relatively low health 
hazard.  Based on the extract yield and other properties, EtOAc is considered as a 
promising alternative solvent to replace traditional CHCl3 extractions in our lab. 
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CHAPTER II 
ISOLATION AND STRUCTURE ELUCIDATION OF CYTOTOXIC SECONDARY 
METABOLITES FROM FILAMENTOUS FUNGI 
 
 
In the history of pharmaceutical industry, natural products have always played an 
important role.   Over the period of 30 years from 1981-2010, approximately 50% of new 
approved drugs were either naturally derived or natural product inspired.16   Newman 
and Cragg reported that of the 175 small molecules, which were approved as the 
anticancer drugs between 1940 and 2010, 74.8% - were other than synthetic, with 
48.6% were either natural products or directly derived a natural product.16  Today, 
natural products are widely accepted for their chemical diversity and well suited to 
provide good scaffolds for the drug design.    
Cancer is the fastest growing disease worldwide and leading cause of death in the 
US; one out of four deaths in US is due to cancer.  In 2008, about 12.7 million people 
were diagnosed with cancer and 7.6 million deaths were caused by cancer worldwide.17  
It is estimated that over 1.6 million Americans will be diagnosed with cancer this year 
while the estimated number of deaths is 577, 190.18  Every day, over 1500 Americans 
are dying of cancer.  Breast cancer was the leading cause of death in women while the 
lung cancer was the leading cause of death in males in 2008.17  In the light of these 
statistics, it is necessary to continue search for anti-cancer agents to inhibit cell survival  
   
22 
pathways in tumor cells and increase the survival rates of cancer patients.The natural 
product-based drugs cover variety of therapeutic indications including anti-infective, anti-
diabetic and anti-cancer.   Since the discovery of Penicillin G19 in 1940, the first natural 
antibiotic isolated from Penicillium chrysogenum , interest in screening the micro-
organisms like bacteria and fungi for drug discovery has grown significantly.    
The role fungi have played in drug discovery cannot be ignored.  For example, 
recently U.S. Food and Drug Administration (FDA) approved a natural product analogue 
fingolimod for the treatment of multiple sclerosis (MS);20 a synthetic compound based on 
fungal secondary metabolite, which clearly demonstrates the importance of fungi as a 
valuable resource for bioactive secondary metabolites.  Earlier publications have pointed 
out that very little of the world’s microbial biodiversity has been available for screening.21  
Hence, targeting fungi may provide isolation of many new cytotoxic compounds for use 
in anticancer drug discovery assays. 
One of the ongoing collaborative projects of our group is to examine the extracts of 
filamentous fungi from the Mycosynthetix library, representing over 55,000 accessions, 
for anti-cancer leads.  Mycosynthetix library has been screened for many biological 
assays but not for the anticancer leads.  Hence, it is a unique and underexplored 
resource for anticancer drug discovery lead.   
This part of the research is focused on using bioactivity-guided fractionation 
methodology for the isolation and purification of bioactive compounds from the 
filamentous fungi, in which purification is guided by the bioassay results.  The primary 
goal was to isolate and structurally elucidate cytotoxic fungal metabolites. Based on the 
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bioactivity for the crude extract, fungus (MSX47782, Mycosynthetix Inc.) was selected 
for further study. 
The Mycosynthetix fungal strains were stored on malt extract slants and a fresh 
culture was grown on a screener scale on solid media, extracted and evaluated for 
cytotoxicity activity. 
 The cytotoxicity measurements against the NCI-H460 human large cell lung 
carcinoma (HTB-177, American Type Culture Collection (ATCC)),22 the MDA-MB-435 
human melanoma (HTB-38, ATCC) and the SW-620 human colon (ATCC) cell lines 
were performed on crude extracts and resulting moderately active fungal samples were 
further analyzed.   
The screener cultures were dereplicated against an in-house library of known 
secondary metabolites in crude culture extracts to avoid re-isolation and re-
characterization of previously known compounds.  Dereplicated samples were 
fractionated via silica gel flash chromatography.    The resulting fractions were submitted 
for bioassay testing.   The active ones were purified via preparative and semi preparative 
HPLC yielding three fungal derived compounds (one new and two known) that displayed 
moderate cytotoxicity against the cancer cell lines.     
Method 
Producing Organisms And Fermentation: 
The Mycosynthetix fungal strain (MSX47782) were stored on malt extract slant and 
transferred periodically.  For the analysis of this fungal strain, fresh cultures were grown 
on a similar slant, and a piece was transferred to a medium containing 2% soy peptone, 
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2% dextrose, and 1% yeast extract (YESD media).  Following incubation (7 days) at 
22°C with agitation, the cultures were used to inoculate 50 mL of a rice medium, 
prepared using rice to which was added a vitamin solution and twice the volume of rice 
with H2O, in a 250 mL Erlenmeyer flask.  This was incubated at 22°C until the cultures 
showed good growth (approximately 14 days) to generate the screening cultures.14,15 
Bioactivity-Guided Fraction: 
To each flask of solid fermentation culture, a mixture of 60 mL of 1:1 MeOH/CHCl3, 
Then, the sample was cut into small pieces with a spatula and stirred overnight (16 h) in 
a shaker at 100 rpm at room temperature.  The sample was filtered by vacuum filtration 
into 250 mL sidearm flasks.  The remaining residues were washed with small volumes of 
MeOH.  To the filtrate, 90 mL of CHCl3 and 150 mL of H2O were added.  The biphasic 
solutions were stirred on a stir plate for 30 min, and then transferred to separatory 
funnels. 
The bottom layers for were drawn off into round-bottom flasks and evaporated to 
dryness.  The organic extracts were then brought up in 50 mL of 1:1 ACN/MeOH and 50 
mL of hexanes.  The biphasic solutions were mixed for an hour and transferred to 
separatory funnels.  The ACN:MeOH layer were evaporated to dryness under vacuum 
and then submitted for bioassay.  This crude extract was tested in the cancer bioassay 
for activity and active ones were dereplicated via methodology developed in Oberlies lab 
using HRESIMS/MS, and samples with no hits proceeded to the fractionation step.    
The dereplicaiton methodology was developed to avoid re-isolation of known fungal 
secondary metabolites in crude extracts.  An in house database was constructed by 
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recording HRMS and MS/MS spectra of compounds isolated to date in the Oberlies lab, 
utilizing both positive and negative ionizations modes, additional information like UV-
absorption maxima and retention times were recorded.  This methodology was 
developed to focus resources on those cultures that are most likely to yield new 
bioactive compounds.  
Fractionation: 
The dereplicated sample was fractionated by normal phase flash silica gel 
chromatography. (Figure 6)  The dereplicated sample was prepared by dissolving it in 
1:1 CHCl3/MeOH and adsorbed onto Celite 545 (Sigma-Aldrich).  Solvent conditions 
were 100% hexane to 100% CHCl3 followed by increasing amounts of MeOH and then 
100% MeOH for the remainder of the run. There were 3 fractions collected. The fractions 
collected were pooled based on their UV/ELSD profiles, dried down and weighed.  
These fractions were screened against, the MDA-MB-435 human melanoma (HTB-38, 
ATCC) and the SW-620 human colon (ATCC) cancer cell lines (Table 4). 
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Figure 6. ISCO flash chromatography of organic extract from MSX47782.* 
 
 
*Blue line is the gradient. Orange line is all wavelength UV.  Green line is ELS detection. 
Pool Fraction Sample Code Weight (mg) 
1 01-12 01020-37-1 1.6 
2 14-27 01020-37-2 9.1 
3 28-End 01020-37-3 37.1 
  Total recovery 47.7 
  % Recovery 70% 
 
 
Human Cancer Cell Panel: 
The human cancer cell panel growth and testing were conducted at the University of 
Illinois at Chicago, College of Pharmacy in the laboratory of Steven M. Swanson.  Initial 
crude extract and the ISCO fractionation bioassays were at concentrations of 20 µg/mL 
and 2 µg/mL.   All samples were dissolved in DMSO and the final concentration was 
≤0.5%. 
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The human cancer cell panel consisted of MDA-MB-435 human melanoma cancer 
cells and SW-620 human cancer cells, both purchased from the American Type Culture 
collection (Manassas, VA).   All cell lines were propagated at 37°C in 5% CO2 in RPMI 
1640 medium supplemented with fetal bovine serum (10%) penicillin (100 units/mL) and 
streptomycin (100 µg/mL).  All cells used were in log phase growth.   The positive control 
was vinblastine tested at 2ng/mL and 1ng/mL:  MDA-MB 435 cells had 30% and 46% 
viable cells, and SW-620 cells had 75% and 74% viable cells, respectively. 
 
Table 4. Bioassay data obtained for flash chromatography fractions of MSX47782.  
All data is percent survival of cell line (sm=starting material prior to fractionation). 
 
Sample ID 
% survival 
(MDA-MB-435) 
% survival 
(SW-620) 
 
20 µg/mL 20 µg/mL 
01020-37-sm 59 39 
01020-37-1 96 92 
01020-37-2 49 33 
01020-37-3 77 57 
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Purification: 
 Active fractions were purified and isolated via preparative and semi preparative 
HPLC.  The preparative HPLC using a gradient that initiated with 40:80 consisting of 
MeCN:H2O (0.1% formic acid) and increased linearly to 40:80 MeCN/H2O within 30 
minutes, at a flow rate of 21 mL/min.  The column used was Phenomenex Synergy C12, 
4µm, 250 x 21.20mm.  Spectra were collected at 204 nm (Figure 7).  In total 9 fractions 
were collected, dried down and yields taken (Table 5).  They were pooled based on the 
UV chromatogram and PDA profiles; the vertical black bars represent fractions.  Based 
on the yields and analytical HPLC profiles, purified fractions 01021-86-2, 01021-86-4 
and 01021-86-5 were further analyzed by NMR and HRMS for chemical structure 
elucidation. 
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Figure 7. a) Preparative HPLC chromatogram of 01020-37-2 @ 335 nm and b) the 
chromatogram showing fractions. 
 
a)   
 
b)   
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Table 5. Preparative HPLC fractions (01020-37-2) pooled based on the 
chromatogram. 
 
Pool Fraction Sample Code Weight (mg)  
1 13-14 01021-86-1 0.65  
2 15-16 01021-86-2 1.18 Compound 1 
3 22-23 01021-86-3 0.72  
4 25 01021-86-4 7.19 Compound 2 
5 34-35 01021-86-5 1.87 Compound 3 
6 44 01021-86-6 0.65  
7 45 01021-86-7 0.22  
8 46-47 01021-86-8 0.49  
9 All Others 01021-86-9 5.46  
 
 
Structure Elucidation Of Active Compounds: 
Isolated fractions, 01021-86-2, 01021-86-4 and 01021-86-5 will be further analyzed 
by 1D-NMR (1H, 13C, DEPT-135), , 2D-NMR (edited-HSQC, HMBC, COSY and NOESY) 
and HRMS for chemical structure elucidation.  
Results And Conclusion 
Throughout the ongoing exploration of extracts of filamentous fungi for cytotoxicity, 
the crude extract of the small scale fermentation of MSX47782 showed moderate activity 
in the human cancer cell panel, 21% cell survival of H460 cells when tested at 20µg/mL.  
This moderately active screener culture was chosen for further analysis due to the belief 
that the cytotoxicity activity of some low concentration compound is masked by other 
high yield non-bioactive compounds.   The crude extract was then fractionated via ISCO 
normal phase chromatography to yield 3 fractions.  These fractions were tested against 
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the MDA-MB-435 and SW-620 human cancer cell lines and fraction 2 showed marginal 
cytotoxic activities on the two cancer cell lines.  Fraction 2 was subjected to further 
purification via preparative HPLC to yield three compounds (1-3).   
Structure Elucidation Of 01021-86-2 (Compound 1): 
01021-86-2 was isolated after one round of prep-HPLC (Figure 7).   Dereplication of 
the compound was attempted by inputting the HRMS (Figure 9) into the Dictionary of 
Natural Products database (DNP ver. 20.1); no matches were found.   
Compound 1 was a white powder (1.18 mg).  The HRMS data was m/z = 213.11232 
[M + H]+ with a second mass peak at m/z = 425.21777 [2M + H]+.  Using the HRMS data, 
a chemical formula of C11H16O4 was calculated, corresponding to an Index of Hydrogen 
Deficiency (IHD) of 4.  The 13C NMR (Figure 10) data showed 11 peaks in total, with 4 of 
those being quaternary carbons [δC 165.9 (C-1), δC 111.1 (C-2), δC 166.6 (C-3), and δC 
120.7 (C-4)], with a peak at δC 61.4 denoting a methoxy group.  
These results were combined with 1H NMR data (Figure 11), the substituents were 
determined as terminal ethyl [δH 0.96 (CH3) and δH 1.70 (CH2)], methoxy (δH 3.95), 
oxymethine (δH 4.55), olifinic (δH 7.35) and methyl (δH 2.09) groups.  The complete 
1H 
and 13C NMR data are shown in Table 6.   
The positions of the substituents and aromatic protons were determined by 2D-NMR.  
The three 2D-NMR experiments utilized here were: COSY (Correlation spectroscopy, 
1H-1H correlations of adjacent protons, Figure 12) , HMBC (Heteronuclear multiple bond 
correlation, long range (2-4 bonds, 3 typically) 1H-13C correlations, Figure 13) and 
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HSQC-edited (Heteronuclear single quantum coherence, direct 1H-13C connectivity 
phase edited giving results similar to DEPT-135 13C NMR, Figure 14).   
Only one spin system was observed in the COSY spectrum (Figure 12) for 
correlations between H-7 (δH 1.70), H-8 (δH 1.49), and H-9 (δH 0.96).  In the HMBC 
experiment (Figure 13), the methyl group at δC 14.0 (C-9) correlated to the adjacent 
methalene carbon at δC 19.3 (C-8) and second correlation observed for the carbon at δC 
39.1 (C-7).  The two methylene groups at δC 39.1 (C-7) and δC 19.3 (C-8) respectively, 
showed correlations to oxymethine at δC 67.9 (C-6) in the HMBC spectrum.  A broad 
singlet corresponding to one of the protons at H-6 (δH 4.55) showed no HSQC 
correlations (Figure 14) to any of the carbons, but useful HMBC correlations were 
observed which helped assign the proton to Hydroxyl group.  Some relevant correlations 
from the olifinic proton helped assemble this unit and carbon NMR shifts justify the 
substitution patterns. At this point only 2 carbons were left to account for; chemical shift 
of this methyl group is consistent with the presence of this subunit to complete the 
structure.   The structure of compound 1 was established as depicted in Figure 8.  
 
Figure 8. Structure of New Compound 1 (01021-86-2). 
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Figure 9. HRMS spectrum for Compound 1 (01021-86-2). 
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Figure 10. 13C NMR of Compound 1 (CDCl3). 
 
 
   
35 
Figure 11. 1H NMR spectrum of Compound 1 (01021-86-2). 
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Figure 12. COSY Spectrum of Compound 1 (01021-86-2). 
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Figure 13. HMBC spectrum of Compound 1 (01021-86-2). 
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Figure 14. HSQC-edited NMR spectrum of Compound 1 (01021-86-2). 
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Table 6. NMR Data for Compound 1 (700 MHZ for 1H, 176 MHz for 13C; Chemical 
Shifts in δ, CDCL3). 
 
Position δC δH Mult  
1 165.9  
2 111.1  
3 166.6  
4 120.7  
5 146.0 7.35 (s) 
6 67.9 4.55 (t) 
7 39.1 1.70 (m) 
8 19.3 1.49 (m) 
9 14.0 0.96 (s) 
10 11.2 2.09 (s) 
11 61.4 3.95 (s) 
 
 
Compound 2 (01021-86-4, 7.19mg) was obtained as an oily sample.  The molecular 
formula was determined as C30H39NO5 by HRMS.  The NMR data, in conjunction with 
HRMS data, identified 2 to be the known compound Cytochalasin H., reported by Tao et 
al in 2007 from the mangrove endophytic fungus Phomopsis sp (ZZF08) obtained from 
the South China Sea coast (Figure 15).24 
Compound 3 (01021-86-5, 1.87mg) was obtained as a yellowy powder.  The HRMS 
data suggested a molecular formula of C15H12O5.  The compound showed distinctive UV 
maxima at 222, 256, 287, 300 and 340 nm, having the typical pattern of alternariol 
derivatives. Positive ESI MS showed molecular ion peak at m/z 273.0761[M+H]+.  The 
spectral data of compound 3 were found in full agreement with those reported for 
Alternariol monomethyl ether, a compound reported in 1983 by Holker et al from the 
Penicillium diversum, (Figure 15).25  
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Figure 15. Chemical structures of compounds 2-3. 
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Table 7. Comparison of 1H and 13C NMR data of Compound 2 (δ in ppm) with 
literature Cytochalasin H., recorded in CDCl3 at 17°C at 500 MHz for 
1H and 125 
MHz for 13C. 
 
 Cytochalasin H.23 Compound 2 
Position 13C 1H 13C 1H 
1 174.3 - 174.4 - 
2 - 5.6 - 5.5 
3 53.8 3.23 53.9 3.2 
4 50.3 2.12 50.5 2.11 
5 32.8 2.77 32.9 2.78 
6 148.0 - 147.9 - 
7 69.7 3.82 69.8 3.82 
8 47.2 2.93 47.3 2.93 
9 51.5 - 51.8 - 
10 45.6 2.85 
2.64 
45.7 2.85 
2.64 
11 14.1 1.0 14.2 0.98 
12 114.1 5.15 
5.35 
114.3 5.11 
5.34 
13 125.9 5.75 127.2 5.72 
14 138.1 5.40 138.8 5.39 
15 42.8 1.77 
2.0 
42.8 1.79 
2.03 
16 31.1 1.8 31.2 1.34 
17 53.8 1.56 
1.86 
53.8 1.57 
1.88 
18 74.3 - 74.5 - 
19 127.0 5.56 126.0 5.84 
20 138.6 5.86 138.2 5.52 
21 77.5 5.55 77.6 5.55 
22 26.5 1.05 26.6 1.04 
23 28.4 1.32 28.5 1.78 
24 170.1  170.3 - 
25 20.9 2.23 21.0 2.23 
26 137.4 - 137.5 - 
27,31 128.9 7.14 129.0 7.14 
28,30 128.9 7.30 129.1 7.31 
29 127.0 7.25 127.2 7.24 
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